TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02062450

Intervention type: DEVICE
Intervention: Primary surgery with Dual Mobility Cup
Description: Hip joint replacement with a hip prosthesis including a Dual Mobility cup to replace the acetabular component.

Intervention type: DEVICE
Intervention: Revision surgery with Dual Mobility Cup
Description: Hip joint replacement with a hip prosthesis including a Dual Mobility cup to replace the acetabular component.
Study: NCT02730910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Purple Wheat Crackers
Description: Whole grain crackers manufactured with purple wheat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Purple Wheat Granola Bars
Description: Whole grain granola bars manufactured with purple wheat
Study: NCT02418325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liberation therapy
Study: NCT06535724

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chronic plantar fasciitis endoscopic debridement coupled with heel spur resection
Description: 1. Preoperative Preparation: popliteal nerve block, patient positioning supine with the operated limb fully externally rotated, spinal anesthesia, tourniquet application.~2. Surgical Procedure:~   * Initial Marking from the heel bone arch to the calcaneal bone to locate the entry point.~  * First Incision and Portal Creation: an initial incision at the palpated site using a size 11 blade; blunt dissection to reveal the plantar fascia; arthroscope entry.~  * Secondary Entry: 3 cm distally from the initial incision; positioning of the arthroscope; additional blunt dissection and obturator insertion.~  * Operative Technique: continuous irrigation with sterile saline; 3.5-mm shaver introduced through the distal portal; meticulous debridement of inflamed and pathological tissue; removal of calcaneal spurs; thinning of the plantar fascia~3. Postoperative Care • Careful monitoring and guided rehabilitation to support optimal healing and recovery.
Study: NCT03020420

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cicatricell Cream
Description: Cream to be applied 2 times a day for 8weeks to 6 months
Study: NCT04098471

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transanal local excision following radiotherapy
Description: transanal local excision following radiotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transanal local excision following radiotherapy
Description: transanal local excision following radiotherapy
Study: NCT02706522

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Allocated to Carbohydrated group
Description: Patients received 400 mL of oral isotonic glucose (No NPO®, Daesang, Korea) 12 hours before anesthesia and 400 mL 2 hours before. CHL composition was standard: 12.5 g of carbohydrate per 100 mL, 12% monosaccharide, 12% disaccharide, 76% polysaccharide, 250 mOsm/kg and 50 kcal.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Allocated to Placebo group
Description: Patients received 400 mL of oral flavored water (Placebo) 12 hours before anesthesia and 400 mL 2 hours before
Study: NCT00690924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcitriol
Description: Oral

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative Study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative Study
Study: NCT03023891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 60 mg tablet once
Study: NCT04223102

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tissue collection
Description: A flexible sigmoidoscopy is a procedure in which a flexible tubularized camera approximately 1 cm in diameter is inserted into the anus and advanced proximally to the sigmoid colon (approximately 20 cm). At that time a rectal biopsy of the tumor will be obtained as well as a sample from \>5cm proximal to the tumor, with a separate biopsy forcep. Tattoo injection, as standard of care, will be performed within 1 cm distal to the tumor to identify the location in the future or for surgical intervention. If there is inability to get proximal to the tumor then a location at least 5 cm adjacent in any direction will be sufficient so long as it is grossly normal appearing.
Study: NCT02579993

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pannus and conjunctival dissection
Description: A complete conjunctival peritomy is performed and the fibrovascular pannus and conjunctiva invading the cornea is dissected from the cornea and limbus.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Human cultivated limbal stem cell transplantation
Description: The amniotic membrane graft cultured with the human limbal stem cell transplantation is placed in the limbic and corneal surface and fixed with fibrin glue. The amniotic membrane is placed with the stroma in contact with the graft and it is sutured.
Study: NCT02093299

Intervention type: DRUG
Intervention: Clopidogrel
Description: a blood sample is drawn on all patients to determine responder status
Study: NCT04618354

Intervention type: OTHER
Intervention: No interventions
Description: This clinical study is a retrospective study, and no interventions have been implemented for patients.

Intervention type: OTHER
Intervention: No interventions
Description: This clinical study is a retrospective study, and no interventions have been implemented for patients.

Intervention type: OTHER
Intervention: No interventions
Description: This clinical study is a retrospective study, and no interventions have been implemented for patients.
Study: NCT03467828

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analyzing
Description: Blood samples will be taken to EDTA containing tubes and then will be analyzed for genetic polymorphisms.
Study: NCT02670512

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telehome Monitoring
Study: NCT02976766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gypenosides
Description: Participants will receive gypenosides 360 mg/day (120 mg three times a day) for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo three times a day for 10 days.
Study: NCT03191084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose THC Marijuana
Description: Dosing via vaporized marijuana using a lower concentration of THC, participants receive this dose on two of the five study visits.
Study: NCT02165163

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes.
Study: NCT01628900

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: care management arm N°1 vs arm N°2
Description: 7 days for mono-antibiotherapy at hospital

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: care management arm N°1 vs arm N°2
Description: 7 days for mono-antibiotherapy at hospital
Study: NCT02872155

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral hydratation
Description: 500 mL of water two hours before computed tomography and 2000 milliliters 24 hours after performing computed tomography
Study: NCT03191084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose THC Marijuana
Description: Dosing via vaporized marijuana using a lower concentration of THC, participants receive this dose on two of the five study visits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose THC Marijuana
Description: Dosing via vaporized marijuana using a higher concentration of THC, participants receive this dose on two of the five study visits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose THC Marijuana
Description: Dosing via vaporized marijuana using a higher concentration of THC, participants receive this dose on two of the five study visits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Marijuana
Description: Dosing via vaporized marijuana with no THC, participants receive this dose on one of the five study visits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Marijuana
Description: Dosing via vaporized marijuana with no THC, participants receive this dose on one of the five study visits.
Study: NCT02872155

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicarbonate endovenous hydratation
Description: Intravenous hydration: sodium (1.6 molar) Bicarbonate 3 mL / kg / h starting one hour before the computed tomography and sodium bicarbonate (1/6 M) 1 mL / kg / h during the hour after computed tomography.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline endovenous hydratation
Description: If there is contraindication for administration of bicarbonate the pattern of intravenous hydration is performed with saline solution: 3 ml / kg / h for 1 hour before the procedure and normal saline 1 mL / kg / hour for hour after computed tomography.
Study: NCT00399477

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rasagiline mesylate
Description: Azilect®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline mesylate plus Mirapex
Description: Mirapex, Azilect®
Study: NCT03213080

Intervention type: DEVICE
Intervention: Targeted Lung Denervation (TLD)
Description: Targeted Lung Denervation (TLD) procedure.
Study: NCT01628900

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care management
Description: Hospital vs home

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care management
Description: Hospital vs home
Study: NCT02838732

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (500 mg per tablet per day, purchased from GNC company)
Study: NCT00399477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline mesylate with Levodopa
Description: Azilect®, Levodopa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline mesylate with Requip
Description: Azilect®, Requip
Study: NCT02543346

Intervention type: DRUG
Group type: OTHER
Intervention: Cetirizine
Description: Participants will receive either cetirizine (10mg tablet, orally) or a placebo (sugar pill) at one of the two treatment visits.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive either a placebo or cetirizine (10mg tablet, orally) at one of the two treatment visits
Study: NCT04083638

Intervention type: DIAGNOSTIC_TEST
Intervention: IFAB
Description: Intestinal Fatty Acid Binding Protein will be taken from all participants before the tx and after the tx

Intervention type: DIAGNOSTIC_TEST
Intervention: IFAB
Description: Intestinal Fatty Acid Binding Protein will be taken from all participants before the tx and after the tx
Study: NCT01697072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilotumumab
Description: Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter factor (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00358722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fermagate
Description: Film coated tablet 500mg
Study: NCT00648271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Tartrate Tablets 25 mg
Description: 2x50mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopressor® Tablets 50 mg
Description: 1x50mg, single dose fed
Study: NCT01697072

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epirubicin
Description: Epirubicin is an anthracycline cytotoxic agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin is an anthracycline cytotoxic agent.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin is a non-cell cycle specific chemotherapeutic agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is a non-cell cycle specific chemotherapeutic agent.
Study: NCT03045029

Intervention type: DRUG
Intervention: Oral treprostinil
Description: Sustained-release oral tablets for TID administration
Study: NCT00788684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: IV infusion once weekly for four doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: ABT-263: oral solution or tablets, once daily dosing until disease progression
Study: NCT01358708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LACTEOL® 340 mg
Description: LACTEOL® 340 mg will be taken for a 4-week duration (28 days) as three capsules a day: two capsules in the morning and one capsule in the evening.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Matched LACTEOL® 340 mg Placebo will be taken for a 4-week duration (28 days) as three capsules a day: two capsules in the morning and one capsule in the evening.
Study: NCT03526796

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Description: Patients were maintained at 2.4 ATA with 100% oxygen for 90 min and then decompressed back to 1 ATA. The treatment duration is 4 weeks and extends to 6 weeks if necessary.
Study: NCT03162354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of a validated Clinical Decision Rule (CDR) as an AHT screening tool
Description: The Clinical Decision Rule (CDR) for AHT reads as follows:~Every acutely head-injured infant or young child hospitalized for intensive care presenting with any one or more of these four variables should be considered high risk and thoroughly evaluated for abuse: (1) any clinically significant respiratory compromise at the scene of injury, during transport, in the Emergency Department, or prior to admission; (2) Any bruising involving the child's ear(s), neck, or torso; (3) Any subdural hemorrhage(s) or fluid collection(s) that are bilateral OR involve the interhemispheric space; (4) Any skull fracture(s) other than an isolated, nondiastatic, linear, parietal, skull fracture.
Study: NCT02821117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre Flash Glucose Monitoring System
Description: Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System masked for 14 days followed by 8 weeks unmasked wear.~During the 2 weeks of masked device wear participants will use the BG strip port for self-monitoring of blood glucose (SMBG). Scanning the sensor at least every 8 hours during this phase.~Followed by 8 weeks of unmasked device wear when participants will use the device (Sensor glucose and SMBG) according to labelling for their day to day management.
Study: NCT01697072

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine is an oral fluoropyrimidine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is an oral fluoropyrimidine.
Study: NCT02124655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Essential oils

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sterile water
Study: NCT03410576

Intervention type: PROCEDURE
Intervention: Carotid artery stenting
Description: Patient undergo elective carotid artery stenting. In this patient group blood sampling was performed at three time points: T1, at the time of the insertion of the arterial line; T2, 60 min after stent insertion; and T3: the first postoperative morning.

Intervention type: PROCEDURE
Intervention: Carotid endarterectomy
Description: Patient undergo elective carotid endarterectomy. Group samples were collected at the following four time points: T1, at the time of the insertion of the arterial line; T2, 60 min after cross-clamp release; T3, the first postoperative morning; and T4, the third postoperative morning. A matched subgroup of patients from the previously obtained data served as a historical control.
Study: NCT00105547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPC-7869
Description: oral 800 mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MPC-7869
Description: Oral BID dosing
Study: NCT02288403

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic interval training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuous training
Study: NCT04628143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nafamostat Mesilate
Description: Administered intravenously as a continuous infusion
Study: NCT01498900

Intervention type: DRUG
Intervention: repaglinide
Description: Prescription according to the product labelling at the physicians' discretion
Study: NCT04383561

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Scaling and root planing (SRP), in four clinical visits

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral hygiene instructions
Description: Oral hygiene instructions includes brushing with the modified Bass technique, interdental cleaning with dental floss and interdental brushes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral hygiene instructions
Description: Oral hygiene instructions includes brushing with the modified Bass technique, interdental cleaning with dental floss and interdental brushes.
Study: NCT00731354

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suction-assisted Lipoplasty
Description: Standard Suction-assisted lipoplasty will be performed on one side of the body to remove excess fat and contour the body in one or more of the following body areas: arm, inner thigh, outer thigh, back

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VASER-assisted lipoplasty
Description: VASER-assisted lipoplasty will be performed on the opposite side of the body to remove excess fat and contour the body in one or more of the following body areas: arm, inner thigh, outer thigh, back
Study: NCT03809975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Community Program
Description: Patient will undergoes 12 weeks of structured and personalized multidisciplinary community-based program, which consists of Physiotherapy, Dietetics and Psychology sessions. Patients will also attend 2 educational sessions. Physiotherapy and educational sessions are mandatory for all participants, while the need for dietetics and psychological interventions are determine using individual's BMI measurements and psychological questionnaires.~Inclusion criteria:~Dietetics: 23.5 \< BMI \<32.5; Psychology: PEG \> 4 or PHQ-4 \> 5 or PAM level \< 3

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current model of care
Description: No controlled set of treatment assigned to patient. It is based totally on the discretion of the attending clinicians. It will generally contain an unspecific number of physiotherapy sessions. Other allied health involvement such as dietetics and psychological interventions will be on an ad hoc basis. In some cases, the orthopaedic surgeon may recommend for surgery.
Study: NCT01307865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injectable poly-L-lactic acid
Description: Each patient will receive up to 1 vial of Sculptra Aesthetic total to both midface complexes at each of 3 treatment sessions, spaced 6 weeks apart.
Study: NCT03061279

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixation by Acutrak headless screw
Description: The fixation provided by the Acutrak headless compression screws provide sufficient fixation to achieve union and a favorable clinical outcome in both horizontal and vertical medial malleolus fractures when compared to bicortical and unicortical screw fixation, tension band wiring, and mini-fragment or buttress plating

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fixation by headed screws, plates, and or wires
Description: DePuy-Synthes Cannulated Cancellous Screws, DePuy-Synthes Cancellous Screws, DePuy-Synthes Cortical Screws, DePuy-Synthes 1/3 Tubular Plate, DePuy-Synthes Locking contrast dynamic compression (LC-DCP) Plate, DePuy-Synthes Pre-contoured Plate, and/or 18g Wire are the alternative methods of treatment of medial malleolus fracture.
Study: NCT03548324

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HHHFNC
Description: Application to HHHFNC to treat respiratory distress syndrome in preterm infants previously demonstrated to be stable on a non-invasive respiratory support (HHHFNC or NCPAP).
Study: NCT01228162

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: effect of muscle relaxation on muscle trauma, control group without relaxation
Description: effect of muscle relaxation on muscle trauma, control group without relaxation
Study: NCT01852448

Intervention type: GENETIC
Intervention: Blood or Saliva Sample Collection
Description: A blood or saliva sample will be obtained for genotyping of TCF7L2 and approximately ten other genes implicated in type 2 diabetes.
Study: NCT01228162

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: effect of muscle relaxation on muscle trauma, control group without relaxation
Description: effect of muscle relaxation on muscle trauma, control group without relaxation
Study: NCT02529020

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mouthguard
Description: Condition of wearing mouthguard

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No mouthguard
Description: Condition without mouthguard
Study: NCT00707148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline (0.9% NaCl) administered as a single 0.5 mL intramuscular injection into the deltoid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Saline (0.9% NaCl) administered as a single 0.5 mL intramuscular injection into the deltoid.
Study: NCT04632264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Initiation of standard postpartum oxytocin immediately following fetal shoulder delivery
Description: The intervention is to determine if initiating oxytocin as soon as the fetus is delivered decreased postpartum blood loss. 30 units in 500 milliliters of 0.9% sodium chloride

Intervention type: OTHER
Group type: OTHER
Intervention: Initiation of standard postpartum oxytocin immediately following placenta delivery
Description: Standard of care includes oxytocin administration post-delivery regardless of delivery mode. This is the comparative group. 30 units in 500 milliliters of 0.9% sodium chloride

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Placebo
Description: Saline placebo will be initiated post placenta delivery (within 15 seconds).

Intervention type: OTHER
Group type: OTHER
Intervention: Saline Placebo
Description: Saline placebo will be initiated post fetal shoulder delivery (within 15 seconds).